Table 3.
Adjunctive therapies for use in COVID-19 in Thailand
| Measure | Purpose/aim |
|---|---|
| Antiviral strategies | |
| Favipiravir + chloroquine or hydroxychloroquine + darunavir/ritonavir or lopinavir/ritonavir | May have therapeutic effects |
| Close monitoring for side effects | To prevent harm by side effects |
| Immunomodulatory therapies | |
| Corticosteroids | |
| Avoid routine use of corticosteroids | Prevention of secondary infections |
| Consider methylprednisolone 1.0–1.5 mg/kg/day for 3–5 consecutive days | Prevent fibrosis |
| Tocilizumab | |
| Consider tocilizumab 4–8 mg/kg/dose (maximum 400 mg) | May mitigate the inflammatory response |
| Cytokine adsorption therapy | |
| Consider hemoperfusion for 3–5 days | May mitigate the inflammatory response |
| Anticoagulant therapy | |
| Always give prophylactic LMWH | Prophylaxis against thromboembolism |
| Consider therapeutic LMWH | Treatment of peripheral thrombosis or pulmonary embolism |
LMWH = low molecular weight heparin.